Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087772 | 0.91 | PIK3CA (0.58) | PIK3CDFGFR3KDRFGFR1FGFR4 | |
| SCHEMBL3097163 | 0.88 | PI4KA (0.55) | PIK3CDFGFR3KDRFGFR1FGFR4 | |
| SCHEMBL3086327 | 0.85 | PIK3CG (0.60) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KA | |
| SCHEMBL3078306 | 0.85 | FGFR3 (0.46) | PIK3CDFGFR3KDRFGFR1FGFR4 | |
| SCHEMBL3086154 | 0.81 | FGFR3 (0.53) | FGFR3KDRFGFR1FGFR4PIK3CA | |
| SCHEMBL3095495 | 0.79 | FGFR3 (0.51) | FGFR3KDRFGFR1FGFR4PIK3CA | |
| SCHEMBL3095294 | 0.78 | FGFR3 (0.55) | PIK3CDFGFR3KDRFGFR1FGFR4 | |
| SCHEMBL3079721 | 0.75 | PIK3CA (0.60) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3090021 | 0.74 | PIK3CB (0.54) | FGFR3KDRFGFR1FGFR4PIK3CA | |
| SCHEMBL3091202 | 0.74 | FGFR3 (0.52) | FGFR3KDRFGFR1FGFR4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| EP-2150255-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | Smithkline Beecham Corporation (US) | 2010-02-10 | — | — | EP | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | PIK3CD 6/4885FGFR3 2690/4885KDR 1697/4885 |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | PIK3CD 6/4885FGFR3 2690/4885KDR 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.